A lawsuit was filed on behalf of investors in Juno Therapeutics Inc shares over alleged securities laws violations. Deadline: September 12, 2016. NASDAQ:JUNO investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 07/18/2016 -- An investor, who purchased shares of Juno Therapeutics Inc (NASDAQ:JUNO), filed a lawsuit in Washington over alleged Securities Laws violations by Juno Therapeutics Inc.
Investors who purchased shares of Juno Therapeutics Inc (NASDAQ:JUNO) have certain options and for certain investors are short and strict deadlines running. Deadline: September 12, 2016. NASDAQ:JUNO investors should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The plaintiff alleges on behalf of purchasers of Juno Therapeutics Inc (NASDAQ:JUNO) common shares between June 4, 2016 and July 7, 2016 , that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between June 4, 2016 and July 7, 2016 the defendants materially misled investors by failing to disclose the May 2016 death of a patient in the Company's Phase 2 trial of product candidate JCAR015 and that these omissions led Juno to trade at artificially inflated prices, and certain insiders participated in the heavy selling of shares in the weeks prior to the disclosure of the death.
On July 7, 2016, Juno Therapeutics Inc announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL), known as the "ROCKET" trial. Juno Therapeutics Inc said that the clinical hold was initiated after two patient deaths one week earlier, which followed the recent addition of fludarabine to the pre-conditioning regimen. Shares of Juno Therapeutics Inc (NASDAQ:JUNO) declined on July 12, 2016 to as low as $27.15 per share.
Those who purchased shares of Juno Therapeutics Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego